Impact of CKD Progression on Cardiovascular Disease Risk in a Contemporary UK Cohort of Individuals With Diabetes

被引:35
作者
Cabrera, Claudia S. [1 ,2 ]
Lee, Alison S. [3 ]
Olsson, Marita [4 ,5 ]
Schnecke, Volker [6 ]
Westman, Klara [7 ]
Lind, Marcus [7 ,8 ]
Greasley, Peter J. [4 ,9 ]
Skrtic, Stanko [7 ,10 ]
机构
[1] AstraZeneca, BioPharmaceut Med, Real World Sci & Digital, Gothenburg, Sweden
[2] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[3] Commonwealth Informat Inc, Waltham, MA USA
[4] AstraZeneca, Gothenburg, Sweden
[5] Chalmers Univ Technol, Dept Math Sci, Gothenburg, Sweden
[6] Novo Nordisk, Soborg, Denmark
[7] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Gothenburg, Sweden
[8] Uddevalla Cent Hosp, NU Hosp Grp, Dept Med, Uddevalla, Sweden
[9] AstraZeneca, Early Clin Dev, Res & Early Dev, Cardiovasc Renal & Metab CVRM,Biopharmaceut R&D, Gothenburg, Sweden
[10] AstraZeneca Gothenburg, Pharmaceut Technol & Dev, Innovat Strategies & External Liaison, Gothenburg, Sweden
关键词
chronic kidney disease; diabetes; epidemiology; heart disease; hypertension; statistical; CHRONIC KIDNEY-DISEASE; FOLLOW-UP; PREVALENCE;
D O I
10.1016/j.ekir.2020.07.029
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: It remains unclear whether an increased progression rate of chronic kidney disease (CKD) adds predictive information regarding cardiovascular disease (CVD) risk. The aim of this study was to evaluate the association between CKD progression, based on estimated glomerular filtration rate (eGFR) slope estimates and the risk for CVD. Methods: We compared the updated eGFR slope calculated over multiple overlapping 2-year periods and the updated mean eGFR. Incident CKD subjects were selected from a prevalent population with diabetes (T2DM). Subjects from the UK Clinical Practice Research Data Link GOLD (CPRD) were followed from CKD diagnosis (n = 30,222) until heart failure (HF), myocardial infarction (MI), ischemic stroke (IS), or a composite end point including all 3 event types (MACE plus), mortality, database dropout, or end of study follow-up. Results: Both the updated eGFR slope and updated mean eGFR were associated with MACE plus and HF. Updated eGFR slope decline of > -3 ml/min/1.73 m(2) increased the risk for MACE plus (adjusted hazard ratio [HR] = 1.45; 95% confidence interval [CI], 1.26-1.67), HF (HR = 1.50; 95% CI, 1.27-1.76), and MI (HR = 1.39; 95% CI, 1.01-1.91). Conclusions: This study strongly supports current evidence that CKD is an independent risk factor for CVD. From a clinical perspective, both rate of progression and cumulative status of CKD describe distinct aspects of the cardiorenal risk among persons with diabetes. This evidence is essential to enable more timely and improved use of treatments in this population.
引用
收藏
页码:1651 / 1660
页数:10
相关论文
共 30 条
[1]   Kidney Disease and Increased Mortality Risk in Type 2 Diabetes [J].
Afkarian, Maryam ;
Sachs, Michael C. ;
Kestenbaum, Bryan ;
Hirsch, Irl B. ;
Tuttle, Katherine R. ;
Hinnmelfarb, Jonathan ;
de Boer, Ian H. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 24 (02) :302-308
[2]  
Aitken GR, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005480
[3]   Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity [J].
Alberti, K. G. M. M. ;
Eckel, Robert H. ;
Grundy, Scott M. ;
Zimmet, Paul Z. ;
Cleeman, James I. ;
Donato, Karen A. ;
Fruchart, Jean-Charles ;
James, W. Philip T. ;
Loria, Catherine M. ;
Smith, Sidney C., Jr. .
CIRCULATION, 2009, 120 (16) :1640-1645
[4]   Chronic kidney disease in US adults with type 2 diabetes: An updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging [J].
Bailey R.A. ;
Wang Y. ;
Zhu V. ;
Rupnow M.F. .
BMC Research Notes, 7 (1)
[5]   Screening early renal failure: Cut-off values for serum creatinine as an indicator of renal impairment [J].
Couchoud, C ;
Pozet, N ;
Labeeuw, M ;
Pouteil-Noble, C .
KIDNEY INTERNATIONAL, 1999, 55 (05) :1878-1884
[6]   Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena [J].
Epstein, Murray .
KIDNEY INTERNATIONAL SUPPLEMENTS, 2016, 6 (01) :20-28
[7]   Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention [J].
Gansevoort, Ron T. ;
Correa-Rotter, Ricardo ;
Hemmelgarn, Brenda R. ;
Jafar, Tazeen H. ;
Heerspink, Hiddo J. Lambers ;
Mann, Johannes F. ;
Matsushita, Kunihiro ;
Wen, Chi Pang .
LANCET, 2013, 382 (9889) :339-352
[8]   Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus [J].
Go, Alan S. ;
Yang, Jingrong ;
Tan, Thida C. ;
Cabrera, Claudia S. ;
Stefansson, Bergur, V ;
Greasley, Peter J. ;
Ordonez, Juan D. .
BMC NEPHROLOGY, 2018, 19
[9]   Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [J].
Go, AS ;
Chertow, GM ;
Fan, DJ ;
McCulloch, CE ;
Hsu, CY .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (13) :1296-1305
[10]   Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation [J].
Greene, Tom ;
Ying, Jian ;
Vonesh, Edward F. ;
Tighiouart, Hocine ;
Levey, Andrew S. ;
Coresh, Josef ;
Herrick, Jennifer S. ;
Imai, Enyu ;
Jafar, Tazeen H. ;
Maes, Bart D. ;
Perrone, Ronald D. ;
del Vecchio, Lucia ;
Wetzels, Jack F. M. ;
Heerspink, Hiddo J. L. ;
Inker, Lesley A. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2019, 30 (09) :1756-1769